AMACR、34βE12双重免疫组化标记在前列腺癌诊断中的应用

Combined immunohistochemical staining of 34βE12 and α-methylacyl-coenzyme A racemase in diagnosis of prostatic carcinoma

目的:通过与α-甲酰辅酶A消旋酶(AMACR)、34βE12抗体单独免疫组化染色效果对比,评估AMACR/34βE12混合双重免疫组化标记对前列腺癌(PCa)的诊断价值。方法:31例前列腺标本,包括PCa 18例、良性前列腺增生(BPH)10例和正常前列腺标本3例;4μm连续切片,分别行AMACR、34βE12抗体单独免疫组化标记以及AMACR/34βE12双重免疫组化标记,比较单独及双重标记结果。结果:所有PCa标本中34βE12单独及双重免疫组化标记均为阴性,而在BPH和正常前列腺中均为阳性。PCa中AMACR单独免疫组化标记的阳性率为88.9%,而在双重免疫组化标记中AMACR阳性率为94.4%。单独应用AMACR免疫组化标记和双重免疫组化标记对诊断PCa无显著差异。结论:应用AMACR/34βE12双重免疫组化标记对诊断PCa具有一定的临床意义,当标本量少以及病变部位细小局限时尤为重要。

Objective：To assess the diagnostic value of combined staining of 34βE12 and α-methylacyl-coenzyme A racemase （34βE12/AMACR） by comparing it with the values of 34βE12 and AMACR staining separately. Methods： Totally 31 prostate specimens （4 μm thickness）, including 18 prostate cancer （PCa） specimens, 10 benign prostatic hyperplasia （BPH） specimens, and 3 normal prostate specimens, were subjected to 34βE12 and AMACR staining separately and a combined staining of both. The results of the 3 staining methods were compared. Results： The results of 34βE12 single staining and combined staining were negative in all 18 PCa specimens and were positive in all BPH and normal specimens. Single AMACR staining was positive in 88.9 % PCa specimens. In the combined staining 94.4% PCa specimens were positively for AMACR. There was an excellent agreement between the AMACR staining profiles in the combined staining and in single AMACR staining. Conclusion： Combined 34βE12/AMACR staining possesses certain diagnostic value for PCa, especially when the sample size is small and the lesions are limited or small.